Merrimack Pharmaceuticals (MACK) Files $172.5M IPO

July 11, 2011 7:28 AM EDT
Get Alerts MACK Hot Sheet
Trade MACK Now!
Join SI Premium – FREE
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker "MACK."

The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

JPMorgan, Merrill Lynch, Bank of America, Cowen & Co

Add Your Comment